IT1250722B - Oligonucleotidi antisenso - Google Patents

Oligonucleotidi antisenso

Info

Publication number
IT1250722B
IT1250722B ITMI912117A ITMI912117A IT1250722B IT 1250722 B IT1250722 B IT 1250722B IT MI912117 A ITMI912117 A IT MI912117A IT MI912117 A ITMI912117 A IT MI912117A IT 1250722 B IT1250722 B IT 1250722B
Authority
IT
Italy
Prior art keywords
modifications
antisense oligonucleotides
concerns
antisense
ability
Prior art date
Application number
ITMI912117A
Other languages
English (en)
Original Assignee
Univ Degli Studi Milano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano filed Critical Univ Degli Studi Milano
Priority to ITMI912117A priority Critical patent/IT1250722B/it
Publication of ITMI912117A0 publication Critical patent/ITMI912117A0/it
Priority to AU23872/92A priority patent/AU2387292A/en
Priority to PCT/EP1992/001745 priority patent/WO1993003053A1/en
Priority to EP92916147A priority patent/EP0605437A1/en
Publication of ITMI912117A1 publication Critical patent/ITMI912117A1/it
Application granted granted Critical
Publication of IT1250722B publication Critical patent/IT1250722B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenzione riguarda un oligonucleotide antisenso che comprende una sequenza di nucleotidi che è caratterizzata dalla sua possibilità di ibridare in condizioni di ibridazione drastiche fino ad una parte della sequenza mRNA del recettore di progesterone umano e inoltre è caratterizzata dalla sua possibilità di bloccare la sintesi del recettore del progesterone umano, e sue modificazioni, riguarda un procedimento per la preparazione di tali oligonucleotici antisenso e di tali modificazioni riguarda composizioni farmaceutiche contenenti tali oligonucleotidi antisenso e tali modificazioni e riguarda l'uso di questi oligonucleotidi antisenso e di loro modificazioni come sostanza terapeutica.
ITMI912117A 1991-07-30 1991-07-30 Oligonucleotidi antisenso IT1250722B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITMI912117A IT1250722B (it) 1991-07-30 1991-07-30 Oligonucleotidi antisenso
AU23872/92A AU2387292A (en) 1991-07-30 1992-07-29 Antisense oligonucleotides
PCT/EP1992/001745 WO1993003053A1 (en) 1991-07-30 1992-07-29 Antisense oligonucleotides
EP92916147A EP0605437A1 (en) 1991-07-30 1992-07-29 Antisense oligonucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912117A IT1250722B (it) 1991-07-30 1991-07-30 Oligonucleotidi antisenso

Publications (3)

Publication Number Publication Date
ITMI912117A0 ITMI912117A0 (it) 1991-07-30
ITMI912117A1 ITMI912117A1 (it) 1993-01-30
IT1250722B true IT1250722B (it) 1995-04-21

Family

ID=11360462

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI912117A IT1250722B (it) 1991-07-30 1991-07-30 Oligonucleotidi antisenso

Country Status (4)

Country Link
EP (1) EP0605437A1 (it)
AU (1) AU2387292A (it)
IT (1) IT1250722B (it)
WO (1) WO1993003053A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043045C (zh) * 1994-04-14 1999-04-21 同济医科大学 抑制内皮素生成的寡核苷酸及其应用
PL1982182T3 (pl) 2006-01-19 2012-09-28 Lattec I/S Nowa konstrukcja przyrządu w postaci suchego paska oraz sposób oznaczania analitu w próbce przy użyciu przyrządu w postaci suchego paska
WO2007082545A1 (en) 2006-01-19 2007-07-26 Lattec I/S Dry stick device and method for determining an analyte in a sample

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907562A1 (de) * 1989-03-09 1990-09-13 Bayer Ag Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
FR2651130B1 (fr) * 1989-08-23 1991-12-13 Roussel Uclaf Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Also Published As

Publication number Publication date
ITMI912117A1 (it) 1993-01-30
EP0605437A1 (en) 1994-07-13
ITMI912117A0 (it) 1991-07-30
WO1993003053A1 (en) 1993-02-18
AU2387292A (en) 1993-03-02

Similar Documents

Publication Publication Date Title
CA2322644A1 (en) Pharmaceutical composition of topiramate
HUP0002296A2 (hu) Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák
KR970706829A (ko) 유전자 발현을 하향 조절하기 위한 2'-치환된 올리고누클레오티드의 사용방법(use of 2' -substituted oligonucleotides to down-regulating gene expression)
CA2227887A1 (en) Pharmaceutical compositions of conjugated estrogens and methods for their use
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PT1162982E (pt) Utilizacao de oligonucleotidos estabilizados pata a preparacao de um meicamento com accao anti-tumor
EP0673252A4 (en) ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES TO THE DOPAMIN RECEPTOR RNA MESSENGER FOR DIAGNOSING AND TREATING NEUROLOGICAL CONDITIONS.
CA2023899A1 (fr) Sequence d'oligonucleotides anti-sens, anti-arn messager du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
HUP0001780A2 (hu) Stabilizált tibolont tartalmazó készítmények és eljárás előállításukra
FR2793793B1 (fr) Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2070664A1 (en) Antisense oligonucleotide inhibition of papillomavirus
KR950703359A (ko) 임신치료를 위한 파라소면(parathormone), 그 생물학적 활성 프래그먼트(fragment) 및 관련 펩티드(peptide)의 용도
IT1250722B (it) Oligonucleotidi antisenso
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
HUP0100044A1 (hu) A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok
WO1994028176A3 (en) Bc200 rna, probes therefor and use thereof
YU56702A (sh) Korišćenje fsh za lečenje neplodnosti
HUP0004577A1 (hu) Kationos nukleinsav transzfekciós ágensek új csoportja
DE60132436D1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
KR890009919A (ko) 4- 헤테로아릴-1,3- 벤조디아제핀 및 2-치환된-α-(헤테로아릴) 벤젠에탄아민, 이의 제조방법 및 약제로서의 이의 용도
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
DE50007708D1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970730